[
    [
        {
            "time": "",
            "original_text": "凯莱英：香港联交所审议公司发行境外上市外资股申请",
            "features": {
                "keywords": [
                    "凯莱英",
                    "香港联交所",
                    "境外上市",
                    "外资股申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英：香港联交所审议公司发行境外上市外资股申请",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：香港联交所上市委员会已审阅公司上市申请",
            "features": {
                "keywords": [
                    "凯莱英",
                    "香港联交所",
                    "上市委员会",
                    "审阅",
                    "上市申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：香港联交所上市委员会已审阅公司上市申请",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药板块2021Q3分析暨11月月报：高基数下增速放缓 板块基本面依旧强劲 把握配置窗口期",
            "features": {
                "keywords": [
                    "医药板块",
                    "2021Q3",
                    "高基数",
                    "增速放缓",
                    "基本面强劲",
                    "配置窗口期"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药板块2021Q3分析暨11月月报：高基数下增速放缓 板块基本面依旧强劲 把握配置窗口期",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【最全】2022年中国医药研发外包(CRO)行业上市公司全方位对比(附业务布局汇总、业绩对比、业务规划等)",
            "features": {
                "keywords": [
                    "医药研发外包",
                    "CRO",
                    "上市公司",
                    "业务布局",
                    "业绩对比",
                    "业务规划"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【最全】2022年中国医药研发外包(CRO)行业上市公司全方位对比(附业务布局汇总、业绩对比、业务规划等)",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]